Beijing's CANbridge Pharma was approved to launch Hunterase® (idursulfase beta injection) in China for Hunter syndrome, a rare disease. It is the first approval in CANbridge's rare disease portfolio and the first enzyme replacement therapy approved in China for Hunter syndrome. CANbridge in-licensed China rights to Hunterase in early 2019 from Korea's GC Pharma. Hunter syndrome is one of the 121 diseases on China's Rare Disease List. More details.... Stock Symbol: (KRX: 006280) Share this with colleagues: // //